Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Toxoplasma gondii | GHMP kinase, N-terminal domain-containing protein | 0.036 | 0.3511 | 1 |
Giardia lamblia | Mevalonate kinase | 0.0237 | 0.1576 | 0.5 |
Mycobacterium ulcerans | phosphomevalonate kinase | 0.0237 | 0.1576 | 0.1271 |
Mycobacterium ulcerans | 4-diphosphocytidyl-2-C-methyl-D-erythritol kinase | 0.0237 | 0.1576 | 0.1271 |
Trypanosoma cruzi | homoserine kinase | 0.0237 | 0.1576 | 0.1576 |
Trypanosoma brucei | galactokinase-like protein, putative | 0.0514 | 0.5923 | 1 |
Trichomonas vaginalis | galactokinase, putative | 0.036 | 0.3511 | 1 |
Leishmania major | galactokinase-like protein | 0.0774 | 1 | 1 |
Mycobacterium ulcerans | galactokinase | 0.0774 | 1 | 1 |
Mycobacterium ulcerans | homoserine kinase | 0.0237 | 0.1576 | 0.1271 |
Trypanosoma cruzi | galactokinase, putative | 0.0774 | 1 | 1 |
Brugia malayi | galactokinase family protein | 0.036 | 0.3511 | 1 |
Treponema pallidum | galactokinase | 0.0673 | 0.8424 | 1 |
Echinococcus granulosus | Mevalonate galactokinase | 0.0237 | 0.1576 | 0.1271 |
Toxoplasma gondii | GHMP kinase, putative | 0.0237 | 0.1576 | 0.3878 |
Trypanosoma cruzi | galactokinase, putative | 0.0673 | 0.8424 | 0.8424 |
Loa Loa (eye worm) | galactokinase | 0.036 | 0.3511 | 1 |
Treponema pallidum | hypothetical protein | 0.0237 | 0.1576 | 0.1519 |
Schistosoma mansoni | galactokinase | 0.036 | 0.3511 | 1 |
Plasmodium falciparum | ATP-dependent Clp protease proteolytic subunit | 0.0159 | 0.0349 | 0.5 |
Trypanosoma cruzi | homoserine kinase | 0.0237 | 0.1576 | 0.1576 |
Trypanosoma cruzi | galactokinase, putative | 0.0774 | 1 | 1 |
Chlamydia trachomatis | ATP-dependent Clp protease proteolytic subunit | 0.0159 | 0.0349 | 0.5 |
Trichomonas vaginalis | galactokinase, putative | 0.036 | 0.3511 | 1 |
Plasmodium vivax | ATP-dependent Clp protease proteolytic subunit, putative | 0.0159 | 0.0349 | 0.5 |
Wolbachia endosymbiont of Brugia malayi | 4-diphosphocytidyl-2-C-methyl-D-erythritol kinase | 0.0237 | 0.1576 | 1 |
Mycobacterium tuberculosis | Probable galactokinase GalK (galactose kinase) | 0.0774 | 1 | 1 |
Trichomonas vaginalis | galactokinase, putative | 0.036 | 0.3511 | 1 |
Chlamydia trachomatis | ATP-dependent Clp protease proteolytic subunit | 0.0159 | 0.0349 | 0.5 |
Trypanosoma cruzi | mevalonate kinase, putative | 0.0237 | 0.1576 | 0.1576 |
Echinococcus granulosus | N acetylgalactosamine kinase | 0.036 | 0.3511 | 0.3277 |
Echinococcus multilocularis | Mevalonate galactokinase | 0.0237 | 0.1576 | 0.1271 |
Loa Loa (eye worm) | hypothetical protein | 0.0237 | 0.1576 | 0.3878 |
Mycobacterium ulcerans | mevalonate kinase, Erg12 | 0.0237 | 0.1576 | 0.1271 |
Trypanosoma cruzi | galactokinase-like protein, putative | 0.0673 | 0.8424 | 0.8424 |
Brugia malayi | mevalonate kinase family protein | 0.0237 | 0.1576 | 0.3878 |
Echinococcus multilocularis | N acetylgalactosamine kinase | 0.036 | 0.3511 | 0.3277 |
Schistosoma mansoni | mevalonate kinase | 0.0237 | 0.1576 | 0.3878 |
Echinococcus multilocularis | galactokinase | 0.0774 | 1 | 1 |
Trichomonas vaginalis | galactokinase, putative | 0.036 | 0.3511 | 1 |
Mycobacterium leprae | Probable 4-diphosphocytidyl-2-C-methyl-D-erythritol kinase IspE (CMK) (4-(cytidine-5'-diphospho)-2-C-methyl-D-erythritol kinase) | 0.0237 | 0.1576 | 1 |
Entamoeba histolytica | galactokinase, putative | 0.0774 | 1 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 28.1838 uM | PubChem BioAssay. qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode). (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 29.0929 uM | PubChem BioAssay. qHTS for induction of synthetic lethality in tumor cells producing 2HG: qHTS for the HT-1080-NT fibrosarcoma cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 35.4813 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of TGF-b. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588856, AID588860] | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.